AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27894336 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin alone
Number of subjects: 80
Study 27894336 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain omega-3 polyunsaturated fatty acids alone
Number of subjects: 80
Study 27894336 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin and long-chain omega-3 polyunsaturated fatty acids (double active)
Number of subjects: 80
Study 27894336 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 80
Study 23891072 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-lowering medications (LLM) at discharge
Number of subjects: 2203
Study 23891072 — intervention group
Group type: COMPARATOR
Intervention: Not discharged on lipid-lowering medications (LLM)
Number of subjects: 2203
Study 23891072 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieving LDL target level of <100 mg/dL
Number of subjects: 2203
Study 23891072 — intervention group
Group type: COMPARATOR
Intervention: Not achieving LDL target level of <100 mg/dL
Number of subjects: 2203
Study 21192262 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (specific agents not detailed)
Number of subjects: 0
Study 21192262 — intervention group
Group type: COMPARATOR
Intervention: Immune checkpoint inhibitors (specific agents not detailed)
Number of subjects: 0
Study 21192262 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer vaccines (specific formulations not detailed)
Number of subjects: 0
Study 19333170 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral transforaminal epidural steroid injections (TF ESIs)
Number of subjects: 0
Study 19333170 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar epidural steroid injections (IL ESIs)
Number of subjects: 0
Study 17556631 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention (handwashing program)
Number of subjects: 87
Study 17556631 — intervention group
Group type: EXPERIMENTAL
Intervention: Expanded intervention (handwashing program, soap for school sinks, and peer hygiene monitors)
Number of subjects: 87
Study 17556631 — intervention group
Group type: COMPARATOR
Intervention: Usual practices (control)
Number of subjects: 87
Study 15383106 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women at high altitude
Number of subjects: 175
Study 15383106 — intervention group
Group type: COMPARATOR
Intervention: Pregnant women at sea level
Number of subjects: 175
Study 11437986 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic xenin at a dose of 4 pmol kg‐1 min‐1 infused for 10 min intravenously
Number of subjects: 29
Study 11437986 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 3453
Study 9085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 100 mg
Number of subjects: 3453
Study 9085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 150 mg
Number of subjects: 3453
Study 9085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg plus Codeine 60 mg
Number of subjects: 3453
Study 9085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 650 mg plus Propoxyphene 100 mg
Number of subjects: 3453
Study 9085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (all doses)
Number of subjects: 3453
Study 9085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg and 100 mg
Number of subjects: 3453
Study 9085303 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (higher doses)
Number of subjects: 3453
Study 9085303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3453
Study 7679166 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine (ISR) 2.5 mg b.i.d. for 4 weeks
Number of subjects: 1647
Study 7679166 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapies (bopindolol, metolazone, enalapril, ISR 5 mg b.i.d.)
Number of subjects: 1647
Study 7679166 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1647
Study 7679166 — intervention group
Group type: EXPERIMENTAL
Intervention: ISR plus diuretics
Number of subjects: 1647
Study 7679166 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (enalapril)
Number of subjects: 1647
Study 3113538 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics given to patients with proved bacteriuria (80 patients)
Number of subjects: 4470
Study 3113538 — intervention group
Group type: COMPARATOR
Intervention: No treatment (8 untreated patients with bacteriuria)
Number of subjects: 4470
Study 3113538 — intervention group
Group type: COMPARATOR
Intervention: Unconfirmed bacteriuria (110 patients)
Number of subjects: 4470
Study 3113538 — intervention group
Group type: COMPARATOR
Intervention: Non-bacteriuric controls (226 patients)
Number of subjects: 4470
Study 3113538 — intervention group
Group type: EXPERIMENTAL
Intervention: Confirmed bacteriuria (226 patients)
Number of subjects: 4470
Study 3113538 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening and treatment program
Number of subjects: 4470
Study 31758325 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 276
Study 28812196 — intervention group
Group type: COMPARATOR
Intervention: FLS training
Number of subjects: 18
Study 28812196 — intervention group
Group type: COMPARATOR
Intervention: VBLaST training
Number of subjects: 18
Study 26460221 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional nursing interventions (not specified in detail)
Number of subjects: 878
Study 26460221 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular weighing
Number of subjects: 878
Study 26460221 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of risk factors
Number of subjects: 878
Study 24643905 — intervention group
Group type: EXPERIMENTAL
Intervention: Odanacatib 50 mg weekly for 2 years
Number of subjects: 214
Study 24643905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 23091195 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (MZ)
Number of subjects: 25
Study 23091195 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 25
Study 19941679 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 ml bittern containing 500 mg of Mg
Number of subjects: 16
Study 19941679 — intervention group
Group type: COMPARATOR
Intervention: 30 g butter with no Mg supplementation (fat-only meal)
Number of subjects: 16
Study 18854289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib/Dexamethasone (VD)
Number of subjects: 0
Study 18854289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib/Lenalidomide/Dexamethasone (VRD)
Number of subjects: 0
Study 18854289 — intervention group
Group type: COMPARATOR
Intervention: Control: Bortezomib/Dexamethasone (VD)
Number of subjects: 0
Study 17085380 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg
Number of subjects: 158
Study 17085380 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol and 2 mg dienogest (E2/dienogest)
Number of subjects: 158
Study 17085380 — intervention group
Group type: COMPARATOR
Intervention: Control group (no menopausal therapy)
Number of subjects: 158
Study 12660934 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV (canarypox vector containing HIV-1 clade B antigens)
Number of subjects: 40
Study 12660934 — intervention group
Group type: COMPARATOR
Intervention: Control vector (rabies virus glycoprotein G gene)
Number of subjects: 40
Study 10823400 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beverages (tea or coffee)
Number of subjects: 30
Study 10823400 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (75 mg)
Number of subjects: 30
Study 10823400 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated beverages
Number of subjects: 30
Study 10823400 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea (75 mg caffeine)
Number of subjects: 30
Study 9038390 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendocrine differentiation identified using Churukian‐Schenk and Garvey silver impregnations.
Number of subjects: 68
Study 9038390 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroendocrine cells identified in 15 cases, 6 with malignant pattern.
Number of subjects: 68
Study 2065499 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium fluoride (50 mg/day p.o.)
Number of subjects: 21
Study 2065499 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (0.5 micrograms/day of 1 alpha (OH)2D3)
Number of subjects: 21
Study 2065499 — intervention group
Group type: COMPARATOR
Intervention: Control groups (not specified)
Number of subjects: 21
Study 6353831 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 33-824 (0.5 mg im injection)
Number of subjects: 8
Study 6353831 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8
Study 30650445 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophage colony-stimulating factor (M-CSF)
Number of subjects: 0
Study 30650445 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0
Study 30650445 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotted plasma (embedding haemophilia monocytes)
Number of subjects: 0
Study 30650445 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin added to a monocyte cell line
Number of subjects: 0
Study 28420909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine lidocaine infusion
Number of subjects: 232
Study 28420909 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical block with lidocaine
Number of subjects: 232
Study 28420909 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tenoxicam
Number of subjects: 232
Study 28420909 — intervention group
Group type: COMPARATOR
Intervention: Control (4ml intravenous normal saline)
Number of subjects: 232
Study 25726411 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson CTP
Number of subjects: 124
Study 25726411 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography (CTA)
Number of subjects: 124
Study 25726411 — intervention group
Group type: COMPARATOR
Intervention: Regadenoson SPECT
Number of subjects: 124
Study 24315520 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-layer compression hosiery
Number of subjects: 457
Study 24315520 — intervention group
Group type: COMPARATOR
Intervention: Four-layer bandage
Number of subjects: 457
Study 24315520 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 457
Study 23882146 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3-dimethylamylamine supplement
Number of subjects: 25
Study 23882146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 19159854 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPSID (computerized angioplasty pressure sensor and inflator device)
Number of subjects: 234
Study 19159854 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPSID (computerized angioplasty pressure sensor and inflator device) with stenting
Number of subjects: 234
Study 19159854 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon inflation (plain old balloon angioplasty)
Number of subjects: 234
Study 19159854 — intervention group
Group type: COMPARATOR
Intervention: Standard balloon inflation (plain old balloon angioplasty) with stenting
Number of subjects: 234
Study 17046034 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (5 g of creatine monohydrate, four times a day for 7 days)
Number of subjects: 0
Study 17046034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17046034 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 0
Study 17046034 — intervention group
Group type: COMPARATOR
Intervention: Creatine supplementation and Placebo
Number of subjects: 0
Study 15899959 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 7522
Study 15899959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7522
Study 11979153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine at a dose of 0.1 mmol/kg
Number of subjects: 82
Study 11979153 — intervention group
Group type: COMPARATOR
Intervention: Gadodiamide at a dose of 0.1 mmol/kg
Number of subjects: 82
Study 11979153 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine at doses of 0.05 and 0.15 mmol/kg and 0.1 and 0.2 mmol/kg
Number of subjects: 82
Study 11979153 — intervention group
Group type: COMPARATOR
Intervention: Gadodiamide at doses of 0.1 and 0.3 mmol/kg
Number of subjects: 82
Study 11979153 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Gadobenate dimeglumine and Gadodiamide)
Number of subjects: 82
Study 9718588 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (1.7 mg/kg)
Number of subjects: 13
Study 8573552 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study 8573552 — intervention group
Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study 2218041 — intervention group
Group type: EXPERIMENTAL
Intervention: PLAX prebrushing rinse
Number of subjects: 0
Study 2218041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 76224 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate alone
Number of subjects: 75
Study 76224 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug regimen
Number of subjects: 75
Study 76224 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin, T.I.C.-mustard, and methotrexate
Number of subjects: 75
Study 76224 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 75
Study 76224 — intervention group
Group type: COMPARATOR
Intervention: Combination chemotherapy
Number of subjects: 75
Study 31586999 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adapalene 0.3%/benzoyl peroxide (A‐BPO) 2.5% with explicative leaflet (G1)
Number of subjects: 126
Study 31586999 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical adapalene 0.3%/benzoyl peroxide (A‐BPO) 2.5% with SMS reminders (G2)
Number of subjects: 126
Study 31586999 — intervention group
Group type: COMPARATOR
Intervention: Topical adapalene 0.3%/benzoyl peroxide (A‐BPO) 2.5% with standard instructions (G3)
Number of subjects: 126
Study 27694498 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist physiotherapy intervention
Number of subjects: 60
Study 27694498 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual control
Number of subjects: 60
Study 25041252 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switching implants placed 1 mm below bone level (test group)
Number of subjects: 56
Study 25041252 — intervention group
Group type: COMPARATOR
Intervention: Implants placed at bone level (control group)
Number of subjects: 56
Study 25041252 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 56
Study 22889358 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with gentamicin-collagen (GS+, n = 52)
Number of subjects: 102
Study 22889358 — intervention group
Group type: COMPARATOR
Intervention: Surgery without gentamicin-collagen (GS-, n = 50)
Number of subjects: 102
Study 21244615 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 105
Study 19232157 — intervention group
Group type: EXPERIMENTAL
Intervention: Below knee cast
Number of subjects: 584
Study 19232157 — intervention group
Group type: EXPERIMENTAL
Intervention: Aircast ankle brace
Number of subjects: 584
Study 19232157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bledsoe boot
Number of subjects: 584
Study 19232157 — intervention group
Group type: COMPARATOR
Intervention: Tubular bandage
Number of subjects: 584
Study 16448890 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 14
Study 16448890 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 14
Study 15065530 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 16
Study 15065530 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 16
Study 11137267 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg doses at 3-day intervals
Number of subjects: 95
Study 11137267 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 9270502 — intervention group
Group type: EXPERIMENTAL
Intervention: SPF 15 sunscreen with high UVA protection
Number of subjects: 160
Study 9270502 — intervention group
Group type: COMPARATOR
Intervention: No sunscreen (control group)
Number of subjects: 160
Study 1388115 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg/day)
Number of subjects: 29
Study 1388115 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine R (20-40 mg b.i.d.)
Number of subjects: 29
Study 3890436 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole (1 g)
Number of subjects: 74
Study 3890436 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (0.2 g)
Number of subjects: 74
Study 3890436 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole
Number of subjects: 74
Study 3890436 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 74
Study 29153463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated LNRT (2.67-3.3 Gy)
Number of subjects: 864
Study 29153463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated LNRT (3.3 Gy for 13 fractions)
Number of subjects: 864
Study 29153463 — intervention group
Group type: COMPARATOR
Intervention: Control group (2.0 Gy fractions)
Number of subjects: 864
Study 26135682 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 124
Study 26135682 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 124
Study 24861959 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselor-delivered intervention
Number of subjects: 385
Study 24861959 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention
Number of subjects: 385
Study 24861959 — intervention group
Group type: COMPARATOR
Intervention: Comparison between counselor and web-based interventions
Number of subjects: 385
Study 21491121 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD40L levels in acute PE patients
Number of subjects: 65
Study 21491121 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 65
Study 19527372 — intervention group
Group type: EXPERIMENTAL
Intervention: Offline adaptive radiotherapy using cone beam CT (CBCT)
Number of subjects: 5
Study 19527372 — intervention group
Group type: EXPERIMENTAL
Intervention: Online adaptive protocol (theoretical)
Number of subjects: 5
Study 19527372 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment plan
Number of subjects: 5
Study 18073060 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine monotherapy (100 mg/d)
Number of subjects: 111
Study 18073060 — intervention group
Group type: COMPARATOR
Intervention: Lamivudine combined with individualized low-dose HBIG
Number of subjects: 111
Study 15224086 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Muscle Test (MMT) for elbow flexion, shoulder flexion, and wrist extension
Number of subjects: 20
Study 15224086 — intervention group
Group type: EXPERIMENTAL
Intervention: Key muscles identified through MMT
Number of subjects: 20
Study 11145630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (trained doctors)
Number of subjects: 110
Study 11145630 — intervention group
Group type: COMPARATOR
Intervention: Control group (untrained doctors)
Number of subjects: 110
Study 9530643 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with arginine, omega-3 fatty acids, and nucleotides (Impact, Sandoz Nutrition)
Number of subjects: 32
Study 9530643 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard enteral diet)
Number of subjects: 32
Study 8129129 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique with Bain system and tightly-fitting anaesthetic face-mask at 8 l.min-1
Number of subjects: 10
Study 8129129 — intervention group
Group type: EXPERIMENTAL
Intervention: Hudson mask with Bain system at 8 l.min-1
Number of subjects: 10
Study 8129129 — intervention group
Group type: COMPARATOR
Intervention: Breathing air
Number of subjects: 10
Study 2657954 — intervention group
Group type: EXPERIMENTAL
Intervention: General practice antenatal care (not specified dosage or duration)
Number of subjects: 0
Study 2657954 — intervention group
Group type: COMPARATOR
Intervention: Smoking status (non-smokers vs smokers)
Number of subjects: 0
Study 2657954 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication prescribed during pregnancy
Number of subjects: 0
Study 2657954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick leave due to low-back pain
Number of subjects: 0
Study 2657954 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization due to hypertension and threatened premature labour
Number of subjects: 0
Study 5307603 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetone-killed agar-grown dried vaccine (vaccine K-66)
Number of subjects: 0
Study 5307603 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed broth-grown sorbed dried vaccine (vaccine G-66)
Number of subjects: 0
Study 5307603 — intervention group
Group type: COMPARATOR
Intervention: Other types of typhoid vaccines
Number of subjects: 0
Study 5307603 — intervention group
Group type: COMPARATOR
Intervention: Heat-killed broth-grown and acetone-killed agar-grown vaccines
Number of subjects: 0
Study 29386030 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled motivation to comply with lifestyle recommendations
Number of subjects: 30
Study 29386030 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous motivation
Number of subjects: 30
Study 29386030 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational internalisation
Number of subjects: 30
Study 29386030 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall motivation for lifestyle change
Number of subjects: 30
Study 28215058 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spinal manipulation (N=28)
Number of subjects: 88
Study 28215058 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic spinal manipulation (N=30)
Number of subjects: 88
Study 28215058 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham-manual contact, N=30)
Number of subjects: 88